AMERICA’S FIRST CRISPR TRIAL IS STILL NEARLY 100% EFFECTIVE 3 YEARS ON

America’s first CRISPR trial is still nearly 100% effective 3 years on. Follow-up results come from one of the longest-running human trials using CRisPR technology to treat a pair of rare genetic blood diseases. The trial focused on two rare blood diseases: beta-thalassemia and sickle cell disease. All but two of 44 patients with TDT were essentially cured of their disease, needing no more blood transfusions.
More Coverage on NEWATLAS